[go: up one dir, main page]

MX2012005968A - 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo. - Google Patents

7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.

Info

Publication number
MX2012005968A
MX2012005968A MX2012005968A MX2012005968A MX2012005968A MX 2012005968 A MX2012005968 A MX 2012005968A MX 2012005968 A MX2012005968 A MX 2012005968A MX 2012005968 A MX2012005968 A MX 2012005968A MX 2012005968 A MX2012005968 A MX 2012005968A
Authority
MX
Mexico
Prior art keywords
methods
crystalline form
bimatoprost
enamide
pent
Prior art date
Application number
MX2012005968A
Other languages
English (en)
Inventor
Gyorgy F Ambrus
Kiomars Karami
Ke Wu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012005968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2012005968A publication Critical patent/MX2012005968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/39—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una nueva forma cristalina de bimatoprost, designado como forma cristalina II. Esta nueva forma cristalina es la forma más estable de bimatoprost conocida hasta la fecha. Además, se encontró que la forma cristalina II del bimatoprost se prepara fácilmente a partir de la forma cristalina I.
MX2012005968A 2009-11-23 2010-11-19 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo. MX2012005968A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26347109P 2009-11-23 2009-11-23
PCT/US2010/057494 WO2011063276A1 (en) 2009-11-23 2010-11-19 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof

Publications (1)

Publication Number Publication Date
MX2012005968A true MX2012005968A (es) 2012-08-15

Family

ID=43639099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005968A MX2012005968A (es) 2009-11-23 2010-11-19 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.

Country Status (20)

Country Link
US (2) US8629185B2 (es)
EP (1) EP2504313A1 (es)
JP (2) JP5921439B2 (es)
KR (1) KR20120085330A (es)
CN (2) CN104367580A (es)
AU (1) AU2010321831B2 (es)
BR (1) BR112012012387A2 (es)
CA (1) CA2781698A1 (es)
CL (1) CL2012001339A1 (es)
CO (1) CO6551754A2 (es)
HK (1) HK1207570A1 (es)
IL (2) IL219959A (es)
IN (1) IN2012DN05209A (es)
MX (1) MX2012005968A (es)
NZ (1) NZ600263A (es)
PH (1) PH12012501098A1 (es)
RU (1) RU2577546C2 (es)
UA (1) UA110696C2 (es)
WO (1) WO2011063276A1 (es)
ZA (1) ZA201203883B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005968A (es) * 2009-11-23 2012-08-15 Allergan Inc 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.
KR102135550B1 (ko) * 2011-06-02 2020-07-21 키노인 제트알티. 프로스타글란딘 아미드의 신규한 제조 방법
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
MX368876B (es) * 2012-12-19 2019-10-21 Sarcode Bioscience Inc Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US9120738B2 (en) 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
CN115677549A (zh) * 2022-10-27 2023-02-03 神隆医药（常熟）有限公司 一种贝美前列素手性异构体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
CA2417489A1 (en) * 2000-07-28 2002-02-07 Maria A. Peral Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2005066256A1 (en) * 2003-12-30 2005-07-21 Metabolix, Inc. Nucleating agents
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
MX2012005968A (es) * 2009-11-23 2012-08-15 Allergan Inc 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.

Also Published As

Publication number Publication date
CO6551754A2 (es) 2012-10-31
JP2016094471A (ja) 2016-05-26
NZ600263A (en) 2014-08-29
RU2012125185A (ru) 2013-12-27
CN102712584A (zh) 2012-10-03
ZA201203883B (en) 2013-01-31
AU2010321831B2 (en) 2016-07-07
BR112012012387A2 (pt) 2019-09-24
IL239892A0 (en) 2015-08-31
US20110152376A1 (en) 2011-06-23
CL2012001339A1 (es) 2012-08-10
US8629185B2 (en) 2014-01-14
EP2504313A1 (en) 2012-10-03
IL219959A (en) 2015-07-30
HK1207570A1 (en) 2016-02-05
US20140113974A1 (en) 2014-04-24
JP5921439B2 (ja) 2016-05-24
KR20120085330A (ko) 2012-07-31
UA110696C2 (uk) 2016-02-10
RU2577546C2 (ru) 2016-03-20
AU2010321831A1 (en) 2012-06-21
CA2781698A1 (en) 2011-05-26
IL219959A0 (en) 2012-07-31
WO2011063276A1 (en) 2011-05-26
CN102712584B (zh) 2014-10-29
JP2013511573A (ja) 2013-04-04
US9181176B2 (en) 2015-11-10
IN2012DN05209A (es) 2015-10-23
PH12012501098A1 (en) 2014-10-14
CN104367580A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
PH12012501098A1 (en) 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
EP2536736A4 (en) PREPARATION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATE PRODUCTS THEREOF
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
GEP20146114B (en) New crystalline form vi of agomelatine, preparation method and application thereof
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
IN2015KN00262A (es)
TN2011000327A1 (en) Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
MY145604A (en) Process for the preparation of chiral 8-(3-aminopiperidine-1-yl)-xanthines
MY164731A (en) Compound
MY148253A (en) Azaadamantane derivatives and methods of use
AU2007257423A8 (en) Purine analogs
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
MX348823B (es) Formulaciones estables de linaclotida.
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2010147302A3 (ko) 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
ZA201003221B (en) Tea composition and process for the manufacture thereof
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX2011012479A (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
TW200740729A (en) Methods for preparing glutamic acid derivatives
IN2015MN00391A (es)
SA112330438B1 (ar) تركيبة صيدلانية محتوية على محصر للعصب العضلي أو عامل ارتخاء للعضل الهيكلي وطريقة تحضيرها

Legal Events

Date Code Title Description
FA Abandonment or withdrawal